Beyond DNA repair: the novel immunological potential of PARP inhibitors.
Loading...
Embargo End Date
ICR Authors
Authors
Chabanon, RM
Soria, J-C
Lord, CJ
Postel-Vinay, S
Soria, J-C
Lord, CJ
Postel-Vinay, S
Document Type
Journal Article
Date
2019-01-01
Date Accepted
2019-02-18
Abstract
Loss of excision repair cross-complementation group 1 (ERCC1), frequently found in lung cancer, and mutations in breast cancer type 1/2 susceptibility genes (BRCA1/2), often found in ovarian, breast and prostate cancers, confer sensitivity to poly-(ADP-ribose) polymerase inhibitors (PARPi). Our work, and that of others, shows that PARPi selectively trigger tumor cell-autonomous immune phenotypes in ERCC1- or BRCA-defective contexts. This suggests that PARPi, used in appropriately selected populations, might mediate their therapeutic effects by potentiating anti-tumor immunity.
Citation
Molecular & cellular oncology, 2019, 6 (2), pp. 1585170 - ?
Source Title
Publisher
TAYLOR & FRANCIS INC
ISSN
2372-3556
eISSN
2372-3556
Collections
Research Team
Gene Function